KEY DETAILS
The FDA approved Mounjaro on Aug. 28 to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high heart risk.
Lilly's recent acquisition spree could add further momentum to its stock price.
Not everyone qualifies for the new Medicare discount on GLP-1 drugs.
Novo's STEP Young trial gives Wegovy another possible growth catalyst.
In STEP Young, 40.4% of children aged 6 to 11 on semaglutide were no longer in the obesity range after 68 weeks, compared with none on placebo.
The FDA approved Eli Lilly's Mounjaro on Aug. 28 to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high heart risk, and investors are asking whether that heart benefit gives the stock a second growth engine beyond weight loss. The timing matters because Lilly has also been buying companies at a rapid clip, and Medicare's new GLP-1 discount is turning out to have real eligibility limits. Novo Nordisk had its own news too, with a Wegovy trial in young children that could reshape how doctors think about treating young children.
Mounjaro's new heart approval, based on the SURPASS-CVOT trial, is drawing attention from investors who have mostly valued Lilly on the strength of its weight loss franchise. In that trial Mounjaro had an 8% lower rate of heart attack, stroke or cardiovascular death than Trulicity, enough to show it was no worse but not enough to prove it was better. If the heart label becomes a distinct selling point, that gives Lilly a second story to tell beyond pounds lost, one that could open the door to a broader set of patients and prescribers who weigh heart risk heavily in their treatment decisions. Some analysts see this as the start of a new phase for the stock, where GLP-1 sales are no longer the only lever driving Lilly's valuation higher. That shift would not happen overnight, but it changes the conversation around what Mounjaro is worth to the company long term.
That broader growth story gets another boost from Lilly's acquisition spree, which has picked up pace in recent months. The company has been adding capabilities and pipeline assets through a series of deals, and some investors are trying to work out how much of that dealmaking could add to the stock price down the road. The logic is straightforward: if Lilly can pair strong existing sales with new assets bought at reasonable prices, the combination gives the stock more than one way to keep climbing. How much of that potential is already priced in remains an open question, and it is one Lilly's next earnings report may help answer.
Not every part of the GLP-1 story looks as favorable for patients, though. Medicare's new discount program for GLP-1 drugs does not cover everyone who might want in, and coverage rules mean some beneficiaries will still face costs the discount was meant to ease. That gap affects people who assumed the program would apply broadly, and it is a reminder that policy headlines do not always translate into access for every patient. Anyone relying on Medicare for these drugs would do well to check their own plan's rules rather than assume the discount applies to them.
While Lilly works through its own set of catalysts, Novo Nordisk added one of its own this week. Its STEP Young trial of Wegovy in children gives the company another data point to point to as it competes for share in a market Lilly is also chasing hard. For Novo, a fresh clinical win serves a similar purpose to Lilly's heart data: it gives investors and prescribers another reason to keep Wegovy in the conversation rather than ceding ground to newer competitors. The two companies are, in effect, racing to add reasons for patients and payers to choose their drug over the other's.
That trial looked at a different population entirely. In STEP Young, 40.4% of children aged 6 to 11 on semaglutide were no longer in the obesity range after 68 weeks, compared with none on placebo, a result that speaks to a much younger age group than the adult weight loss market most GLP-1 coverage focuses on. That finding could matter for parents and pediatricians weighing treatment options for children who have not responded to other approaches, though any decision about a child's treatment should involve their own doctor rather than a headline number. It also gives Novo another avenue for Wegovy's use beyond the adult market Lilly is competing hardest for.
Taken together, today's news shows two large companies working from different angles to extend their GLP-1 franchises, Lilly through a new heart approval and acquisitions, Novo through a new trial in children. For readers with a financial interest, the near-term signal to watch is how analysts and Lilly's next earnings call treat the heart data and deal spree separately, since conflating the two could overstate what either has actually proven. For readers with a personal or family interest in these drugs, the more useful step is to check your own Medicare plan's rules on the GLP-1 discount and, if a child's weight is the concern, to raise the pediatric study with their doctor directly rather than acting on the headline alone.
Read this on GLP-1 Nation: https://glp1nation.com/edition/43
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.